AEON (AEON Biopharma) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


AEON AEON Biopharma Inc AEON
10 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is AEON Biopharma Tariff Resilience Score?

AEON Biopharma AEON -2.66% 10 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates AEON with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, AEON Biopharma ranks better than 90.39% on this metric.

AEON Biopharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AEON Biopharma has AEON Biopharma has moderate exposure to tariffs due to its reliance on global supply chains for raw materials. However, its primary market is domestic, reducing direct tariff impact. The company has some pricing power and alternative suppliers, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AEON Biopharma might have Highly Resilient.

AEON Biopharma  (AMEX:AEON) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AEON Biopharma Tariff Resilience Score Related Terms

AEON vs ZIVO, CVM, ATOS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AEON Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEON Biopharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Tariff Resilience Score falls into.


AEON
10GF Score
AEON Biopharma Inc AEON
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AEON Biopharma (AEON) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AEON Biopharma ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is AEON Biopharma's Tariff Resilience Score too high?
AEON Biopharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. AEON Biopharma's value of 7 is 75% above this industry median. Based on the distribution chart, AEON Biopharma ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AEON Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's Tariff Resilience Score compare to ZIVO and CVM?
According to the Biotechnology industry distribution chart, AEON Biopharma ranks #132 out of 1374 companies for Tariff Resilience Score. This places AEON Biopharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AEON Biopharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AEON Biopharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AEON Biopharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. AEON Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AEON Biopharma (AEON), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AEON Biopharma Business Description

Address 5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
10GF Score

Get the complete analysis for AEON

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price